Page 18 - hypertension_newsletter7

REFLECTIONS
Hypertension
Hypertension Global Newsletter #7 2024

CONFERENCE CORNER Hypertension

The ESC Congress, hosted in London, England on Aug 30th – Sept 2nd 2024, is the annual meeting
of the European Society of Cardiology. We present below some abstracts of interest that may have an
impact on clinical practice. Please click on the links to explore the abstracts in more detail.

RISK FACTORS AND LIFESTYLE MODIFICATION IN HYPERTENSION

1. Arterial hypertension in the era of obesity bias: The impact of obesity status on pharmacological treatment
intensification in patients with diabetes. Telo GH, et al. Eur Heart J. 2024;45(Suppl 1): ehae666.2578.
2. Individual and cumulative effects of socioeconomic factors on hypertension in low- and middle-income countries: A
cross-sectional study of 1,071,070 individuals from 26 nationally representative survey. Mishra SR, et al. Eur Heart J.
2024;45(Suppl 1): ehae666.2559.

BLOOD PRESSURE TARGETS AND EPIDEMIOLOGY

3. Blood pressure control and cardiovascular risk assessment in patients with hypertension: A pooled analysis of
6 countries in Eastern and Southern Europe (SNAPSHOT study). Camafort M, et al. Eur Heart J. 2024;45(Suppl 1):
ehae666.2549.

4. Comparison of intensive treatment versus standard treatment in lowering blood pressure and its association with
cognitive decline and dementia: A systematic review and meta-analysis. Bresciani L, et al. Eur Heart J. 2024;45(Suppl
1): ehae666.2544.

HYPERTENSION PHENOTYPES

5. Association of cardio-cerebrovascular death with isolated diastolic hypertension: A nationally representative
survey of 85,138 adults. Zhao S, Zhang Y. Eur Heart J. 2024;45(Suppl 1): ehae666.2539.

6. Association of different timepoint and threshold of time-in-target-range and MACEs: Insight from the SPRINT study.
Moran LI, et al. Eur Heart J. 2024;45(Suppl 1): ehae666.2570.
PHARMACOLOGICAL MANAGEMENT OF HYPERTENSION

7. Subgroup results from KARDIA-2: Impact of demographic and baseline disease characteristics on zilebesiran
response in patients with hypertension uncontrolled by a standard oral antihypertensive. Saxena M, et al. Eur Heart
J. 2024;45(Suppl 1): ehae666.2593.

8. Blood pressure lowering efficacy of antihypertensive drugs and their combinations: A systematic review and
meta-analysis of 500 randomised, double-blind placebo-controlled trials. Wang N, et al. Eur Heart J. 2024;45(Suppl 1):
ehae666.2594. al

9. Adherence to anti-hypertensive therapy with perindopril-based single-pill versus free-pill combinations: A 10-year
real-world analysis in Italy. Vintila AM, et al. Eur Heart J. 2024;45(Suppl 1): ehae666.2586.
10. Real-world analysis exploring the association between anti-hypertensive therapy with perindopril-based single-
pill combinations (SPC) and cardiovascular outcomes and all-cause mortality in Italy. Wolf S, et al. Eur Heart J.
2024;45(Suppl 1): ehae666.2585.

TABLE OF CONTENTS